Skip to main content
Download PDF

Regional cerebral tau predicts decline in everyday functioning across the Alzheimer’s disease spectrum

Alzheimer's Research & Therapy volume 15, Article number: 120 (2023) Cite this article

Abstract

Background

Emerging difficulty performing cognitively complex everyday tasks, or ‘instrumental activities of daily living’ (IADL) may be an early clinical sign of Alzheimer’s disease (AD). We aimed to investigate how changes over time in everyday functioning relate to cerebral tau burden across the AD clinical spectrum.

Methods

We included 581 participants (73.9 ± 7.6 years old; 52% female) from the Alzheimer’s Disease Neuroimaging Initiative who underwent tau positron emission tomography (PET) and completed at least two assessments of the Functional Activities Questionnaire (FAQ). Participants were classified as cognitively normal (n = 334) or symptomatic (n = 247). We analyzed the association between longitudinal FAQ scores and baseline tau in six temporal, parietal, and frontal brain regions in mixed-effects models. Models were run in the entire sample, as well as stratified by diagnostic group (cognitively normal or symptomatic). We additionally investigated tau-PET adjusted for, as well as interacting with, amyloid-β.

Results

Greater tau burden in several frontal, temporal, and parietal regions was associated with steeper decline over time in everyday functioning. These findings remained when adjusting for baseline global cortical amyloid-β; amyloid-β itself was only associated with change over time in FAQ scores when tau was not included in the model. When stratifying by diagnostic group, most associations between tau and everyday functioning, adjusted for amyloid-β, were present only in the symptomatic group.

Conclusions

The rate of change in everyday functioning is related to baseline tau burden in various brain regions, more strongly so than global cortical amyloid-β, specifically in cognitively symptomatic individuals. Longitudinal studies in incident dementia populations are needed to better understand functional changes in response to AD pathology across the disease.

Background

Everyday functioning can be represented in “instrumental activities of daily living” (IADL), such as managing finances or preparing meals. Difficulties with performing these cognitively complex activities emerge due to increasing cognitive impairment in Alzheimer’s disease (AD) and related disorders. AD is biologically defined by abnormal levels of amyloid-β and tau [1], which accumulate over decades preceding a dementia diagnosis. Everyday functioning constitutes a clinically relevant outcome, as it reflects an individual’s capacity to live independently. While impairment in everyday functioning traditionally hallmarks the start of the dementia stage, it is known that decline in everyday functioning occurs in prodromal and even preclinical stages of AD [2,3,4].

Everyday functioning is usually assessed using observer-reported outcome measures that rely on information from someone close to the patient (e.g., a spouse or close friend). An example of such measure is the Functional Activities Questionnaire (FAQ), a brief, ten-item questionnaire that assesses various cognitively complex activities [5], including the ability to assemble tax records or make a cup of coffee. A recent study showed that the FAQ is reliable and strongly correlated with cognitive measures among symptomatic individuals [6], while reliability was somewhat restricted among individuals who are cognitively normal. This was likely due to a limited range in scores in the cognitively normal group. Marshall and colleagues [7] previously identified specific FAQ questions that predicted progression from normal cognition to mild cognitive impairment (MCI).

Comparable to cognitive changes, it is hypothesized that the accumulation of cortical amyloid and cerebral tau underlie deterioration of everyday functioning. Indeed, studies have shown that difficulties performing basic and more cognitively complex activities of daily living have been associated with elevated levels of cortical amyloid-β [8, 9]. Increased cerebral tau has also been associated with early functional changes [10, 11], as have loss of cortical thickness [12] and glucose hypometabolism [13] in various temporal and parietal regions. Finally, tau deposition in frontal regions has also been associated with impairment of everyday functioning in later disease stages [11, 14]. Most of these studies have been cross-sectional and in symptomatic individuals, and less is currently known about the relationship between tau and longitudinal changes in everyday functioning.

In this study, we aimed to investigate how cerebral tau in various regions of interest relates to changes over time in everyday functioning in individuals who are either cognitively normal (CN) or who have been diagnosed with MCI or dementia. We hypothesized that a greater tau burden at baseline would associate with a more rapid decline of everyday functioning over time across diagnostic groups, but more so in symptomatic individuals.

Methods

Participants

We selected 633 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI; adni.loni.usc.edu) who underwent tau positron emission tomography (PET) scans and who completed at least two functional assessments. Participants were included in ADNI-2 (2011–2016) and ADNI-3 (2016–2022). Participants were categorized as CN, MCI or dementia, based on the ADNI criteria.

We excluded participants with a 15-item Geriatric Depression Scale (GDS; [15]) of ≥ 6 at baseline (n = 18) or with missing covariates at baseline (n = 34), resulting in a total sample size of 581.

Tau and amyloid-β PET imaging

Cerebral tau and amyloid-β deposition were assessed using PET scans, with the [18F]-flortaucipir (for tau) and [18F]-florbetapir or [18F]-florbetaben (for amyloid-β) tracers. More details on acquisition and processing methods for these PET scans are described on the ADNI website at https://adni.loni.usc.edu/methods/pet-analysis-method/pet-analysis/.

In brief, for tau images, the mean flortaucipir uptake within each FreeSurfer-defined region of interest (ROI) was calculated and then intensity normalized by the inferior cerebellum reference region. Based on the results of previous studies [10, 11, 14], the ROIs chosen for this investigation were the bilateral entorhinal cortex, inferior temporal, precuneus, posterior cingulate, supramarginal, and the dorsolateral prefrontal (DLPF) composite consisting of the average of the caudal middle frontal, rostral middle frontal, and superior frontal regions.

Amyloid-β PET scans within one year of the baseline tau scan were available for nearly all participants (n = 570, 98%). For each tracer separately, an amyloid-β summary standard uptake volume ratio (SUVr) was calculated using a cortical composite and intensity normalized by the whole cerebellum reference region. Continuous values from both tracers were aligned with each other using centiloids, according to the amyloid-β PET processing methods as described in the ADNI study material.

Measures

We used the 10-item Functional Activities Questionnaire (FAQ) to assess everyday functioning [5]. Each item is rated on a four-point scale, ranging from “normal” to “dependent”. A total score is obtained by summing the items, resulting in a score ranging from 0 to 30 where higher scores represent more functional dependence.

We used overall performance on the five immediate recall trials of the Rey Auditory Verbal Learning Test (RAVLT; [16]) as an assessment of episodic memory functioning. The American National Adult Reading Test (AmNART) was used as a test of premorbid intelligence [17]. Higher scores on the RAVLT and AmNART indicate better performance. Seconds to complete part B of the Trail Making Test (TMT) [18] was used as a measure of mental flexibility, an aspect of executive functioning. Higher scores on the TMT-B represent worse performance.

Statistical analyses

All analyses were run in R version 4.2.0 [19]. Baseline differences between diagnostic groups were tested using Wilcoxon rank sum test, Pearson’s Chi-squared test, or Fisher’s exact test as appropriate. Correlations between the cognitive tests and FAQ at baseline were computed using Spearman’s ρ correlation coefficient.

The associations between baseline tau-PET and amyloid-PET and changes over time in FAQ were investigated using a binomial mixed-effects model. This model was selected to account for dual floor and ceiling effects in the FAQ total score trajectories, as individual trajectories tended to follow a sigmoid curve, asymptoting at the measure’s floor and ceiling with an intermediate period of steep increase. For the dependent variable in the binomial mixed-effect models, we scaled the total FAQ scores by their maximum of 30 so that scores fell between 0 and 1, representing each participant’s score as a proportion of the maximum FAQ score. A logistic sigmoid curve was then to the result. These models were run using the “glmmTMB” package and showed excellent fit. Regular linear mixed models were additionally run for ease of interpretability using the “lmerTest” package and are displayed in the Supplementary Material, though they showed poor fit. First, we analyzed unadjusted change in FAQ over time in the whole sample, as well as stratified by diagnostic group, using random slopes and intercepts by subject. Then, separate models were run analyzing the association between longitudinal FAQ scores and the interaction of time with (1) baseline tau-PET, (2) baseline amyloid-PET, and (3) tau-PET adjusted for amyloid-PET. These models included tau-PET and/or amyloid-PET by time interactions. For models involving tau-PET, a separate model was run for each ROI. For models including centiloids, one individual with an outlying centiloid value was excluded. Reported model p-values are adjusted for multiple comparisons using the False Discovery Rate (FDR) method. All models were adjusted for baseline age, gender, and the interaction of baseline age with time. We additionally adjusted models for baseline RAVLT, AmNART, TMT-B, and determined that adding cognitive functioning improved model fits as based on the Akaike Information Criterion.

For secondary analyses, we predicted longitudinal FAQ from tau-PET with an amyloid-PET adjustment in the CN and symptomatic groups separately. In CN only models, one outlying individual was excluded from analyses, because their FAQ score increased rapidly from no impairment to severe impairment at their second follow-up visit. Additionally, we examined the three-way interaction between tau-PET, amyloid-PET, and time in predicting the FAQ total score within the full sample. All models used the same random-effects structure and covariates as above.

Sensitivity analyses were run with a grouped version of the amyloid-PET measure, with Aβ+ indicating amyloid-β levels elevated above a threshold (1.11 SUVr for [18F]-florbetapir or 1.08 SUVr for [18F]-florbetaben) and Aβ- indicating not elevated.

Results

We included 581 participants (73.9 ± 7.6 years old, 52% female) who were either CN (n = 334, 57%) or had a diagnosis of MCI (n = 191, 33%) or Alzheimer’s disease dementia (AD, n = 56, 10%). These last two groups were combined into a ‘symptomatic’ group. Symptomatic participants were older, more often male and had fewer years of education, compared to the CN group. Demographic characteristics are displayed in Table 1.

Table 1 Baseline demographics and characteristics
Full size table

At baseline, the overall average FAQ score was 2.4 ± 5.0. CN participants had a significantly lower FAQ at baseline of 0.2 ± 0.9, compared to 5.3 ± 6.6 among symptomatic participants (p < 0.001). Baseline FAQ total scores were correlated with measures of executive functioning (Spearman’s ρ = 0.46, p < 0.001) and episodic memory (ρ = -0.50, p < 0.001), as well as premorbid intelligence (ρ = -0.25, p < 0.001). These correlations were less evident in the CN participants, with only the executive functioning task showing a significant correlation (ρ = 0.16, p = 0.003; both others p > 0.05).

Overall, unadjusted FAQ scores showed no significant change over time (odds ratio (OR) = 0.98, 95% confidence interval (95%CI) = [0.83, 1.16], p = 0.843). When stratifying by diagnostic group, it appeared CN participants’ odds for increasing FAQ were not elevated (OR = 1.01, 95%CI = [0.60, 1.69], p = 0.976), while participants who were symptomatic had higher odds for increasing FAQ scores over time (OR = 1.24, 95%CI = [1.12, 1.37], p < 0.001), representing a 24% increase in their degree of impairment as measured across FAQ items.

Including adjustments for baseline cognitive performance altered the estimates for change in everyday functioning over time only marginally; therefore, only the adjusted models are reported below. Models not adjusted for baseline cognitive performance are displayed in the Supplementary Material. Tau accumulation in all investigated ROIs was associated with an increase in FAQ scores over time in both cognitively normal and symptomatic individuals combined (all p < 0.001). This association remained significant in all brain regions (all p < 0.001) after adjusting for amyloid-PET. Among CN participants, tau in the entorhinal and inferior temporal cortex was significantly associated with changes on the FAQ, but only tau in the inferior temporal cortex remained significantly associated with FAQ changes when adding amyloid to the model (p = 0.035; all other p > 0.05). In symptomatic individuals, we observed a significant association between baseline tau-PET in all ROIs and change on the FAQ, both without and with adjustment for amyloid. All estimates are displayed in Table 2 and associations for the amyloid-adjusted models are visualized in Fig. 1.

Table 2 Association between baseline amyloid-PET and tau-PET and change in FAQ scores over time, in binomial models
Full size table
Fig. 1
figure 1

Association between tau and change in FAQ scores over time, stratified by diagnostic group

Full size image

We additionally ran models with an interaction between tau, amyloid, and time. These three-way interactions were not significant, neither in the whole group nor in the diagnostic groups (see Table 2).

In sensitivity analyses with dichotomized amyloid, results remained the same. For ease of interpretability, we also ran all above binomial models as linear models. Linear models had suboptimal fit, but results were comparable to the binomial models, except that tau in the precuneus and supramarginal cortex was also associated with change in FAQ over time. These associations disappeared when including amyloid-PET in the model. All sensitivity analyses are shown in the Supplementary Material.

Figure 1 displays the association between change in FAQ scores over time and baseline tau accumulation in the ROIs, stratified for diagnostic group. For visualization purposes, we divided tau-PET into three groups, representing the mean tau-PET level (medium) and one standard deviation below (low) and above (high) the mean. The curves are adjusted for amyloid, with age, gender, RAVLT, TMT-B, AmNART, and the interaction of age with time as covariates.

Discussion

In this study, we demonstrated that baseline levels of tau in various cerebral regions were associated with decline over time in cognitively complex activities of daily living, as measured by the FAQ. In individuals who were initially cognitively normal, baseline tau in the entorhinal and inferior temporal regions was associated with decline in everyday functioning over time, even when adjusting for global amyloid-β burden. In symptomatic individuals, tau in all investigated areas was related to future decline in everyday functioning, even when accounting for amyloid-β.

On average, everyday functioning declined over time in the entire sample. As expected, the change in everyday functioning was larger in symptomatic than in CN individuals. In fact, everyday functioning only marginally changed among individuals who were CN at inclusion. It has been described previously that everyday functioning as measured using observer-reported outcome measures may decline in preclinical and prodromal disease stages [3, 20,21,22,23]. It is possible that, with a more extensive and fine-grained instrument and/or longer follow-up times, we would have been able to capture even more changes in everyday functioning.

Nevertheless, our findings show a relationship between everyday functioning and cerebral tau in temporal, parietal, and frontal regions both in symptomatic and CN individuals. Various previous studies have shown a cross-sectional relationship between tau and everyday functioning, most evidently in temporal, frontal and parietal brain regions [10, 11, 14, 24], which informed our selection of regions to investigate in the present study. However, the association between longitudinal changes in everyday functioning and tau is less well-studied. Here, we demonstrate that those who are cognitively symptomatic and who have higher (i.e., more abnormal) levels of tau in several (medial) temporal, frontal, and parietal brain regions showed more progression of difficulties with everyday functioning over an average time of two-and-a-half years. Elevated levels of tau in the entorhinal and inferior temporal cortices were even related to a decline in everyday functioning in cognitively normal individuals, when not considering global amyloid-β burden. Even when accounting for global amyloid-β, tau in the inferior temporal cortex was related to a greater change in everyday functioning. The regional differences between cognitively normal and symptomatic individuals can be explained by the fact that the latter group is in a later disease stage. As AD progresses, brain pathology spreads through the cortex. Symptomatic individuals have more cognitive—and functional—impairments. As such, we were more likely to find associations in more brain regions in symptomatic individuals. Temporal regions are known to accumulate tau, but not necessarily amyloid-β, in early disease stages [25]. This might explain why we found a relationship between inferior temporal tau and functional change even in individuals in an early disease stage.

Regarding global cortical amyloid, only cognitively symptomatic participants with more abnormal levels of amyloid showed more decline of everyday functioning. We did not observe such a relationship in CN individuals, which might be explained by either the lower levels of amyloid, or the limited changes in everyday functioning in this group. We further attempted to model the interaction between tau and amyloid in the change in everyday functioning and found that elevated global cortical amyloid and elevated tau in the entorhinal, inferior temporal, posterior cingulate and supramarginal cortices predicted more decline in everyday functioning in the entire sample. Hanseeuw and colleagues [26] previously demonstrated a sequential relationship between amyloid, tau, and cognition, where those with higher levels of amyloid and more increase in tau became cognitively impaired. It is conceivable that a similar process underlies impairment in everyday functioning. Our results suggest an interplay between the two proteins in subsequent functional decline, although our study did not include repeated measures of amyloid or tau. It should be noted that the combined effect of elevated amyloid and tau was visible only the total group, and not in either the CN or symptomatic subgroups separately. A potential explanation for this is that the two subgroups may have been too small to support the modeling of complex interactions of variables. The lack of sufficient variability in levels of amyloid, tau, or everyday functioning in either group alone may be another possible reason for the instability of this finding.

Everyday functioning is conceptually close to cognitive functioning, as the performance of complex activities relies on various cognitive functions [27]. Therefore, our findings track with previous studies showing that tau abnormalities are related to cognitive impairment [28], and more strongly so than amyloid [29]. That said, our findings that the estimates of change in everyday functioning were not altered substantially when adjusting for baseline cognitive performance led us to believe that there is unique functional change in relation to tau and amyloid that is not explained by performance on cognitive tests. This may imply that function is not simply a proxy of cognition in everyday life. More studies are needed where both everyday functioning and cognitive test performance are measured repeatedly to better understand how cognitive and functional changes relate to one another in the context of AD.

We made use of the FAQ in this study, which is a brief questionnaire that has recently been shown to have good reliability and validity [6, 30]. Further, it seems to have limited bias for education, ethnicity, race, language, and sex [30]. An advantage of the FAQ is that it comprises only ten questions and therefore poses very little burden on the person completing it. However, we observed a substantial floor effect in CN individuals, with relatively little change over two-and-a-half years. More sensitive measures of IADL performance may be capable of capturing more subtle changes, which seems particularly relevant in early disease stages. Performance-based and digital tools in particular have great potential to provide fine-grained measurements of objective IADL performance at early stages of AD.

Limitations

This study had a few limitations. First, the follow-up duration was relatively short, with an average of two-and-a-half years. Especially in CN individuals, notable changes in IADL may take longer to evolve. Second, our sample was mostly comprised of relatively highly educated White individuals, limiting the generalizability of our findings to underrepresented groups. Third, the IADL measure we used, the FAQ, had both floor and ceiling effects in the current sample, though the binomial model accounted for this effect. Strengths of this study included the availability of regional tau measures in several relevant brain areas, as well as repeated assessments of IADL performance for a relatively large longitudinal imaging cohort.

Conclusion

In conclusion, decline in everyday functioning in AD seems to be driven by tau in various areas of the temporal, parietal, and frontal lobes, especially in mildly cognitively symptomatic individuals. Future studies should further investigate the causal role of tau in the performance of complex everyday activities, including repeated measures of tau and more sensitive measures of IADL in more diverse samples.

Availability of data and materials

The datasets used and/or analyzed during the current study are available through the LONI Image and Data Archive repository, upon registration via https://adni.loni.usc.edu/.

Abbreviations

AD:

Alzheimer’s disease

ADNI:

Alzheimer’s Disease Neuroimaging Initiative

AmNART:

American National Adult Reading Test

CN:

Cognitively normal

DLPF:

Dorsolateral prefrontal cortex

FAQ:

Functional Activities Questionnaire

FDR:

False Discovery Rate

GDS:

Geriatric Depression Scale

IADL:

Instrumental activities of daily living

LMM:

Linear mixed model

MCI:

Mild cognitive impairment

MMSE:

Mini-Mental State Examination

OR:

Odds ratio

RAVLT:

Rey Auditory Verbal Learning Test

ROI:

Region of interest

SUVr:

Standard uptake volume ratio

TMT:

Trail Making Test

VIQ:

Verbal intelligence quotient

95%CI:

95% Confidence interval

References

  1. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer’s disease. The Lancet. 2021;397(10284):1577–90.

    Article  CAS  Google Scholar 

  2. Marshall GA, Amariglio RE, Sperling RA, Rentz DM. Activities of daily living: where do they fit in the diagnosis of Alzheimer’s disease? Neurodegener Dis Manag. 2012;2(5):483–91.

    Article  PubMed  Google Scholar 

  3. Dubbelman MA, Jutten RJ, TomaszewskiFarias SE, Amariglio RE, Buckley RF, Visser PJ, et al. Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum. Alzheimers Res Ther. 2020;12(1):138.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Verlinden VJA, Van der Geest JN, De Bruijn RFAG, Hofman A, Koudstaal PJ, Arfan IM. Trajectories of decline in cognition and daily functioning in preclinical dementia. Alzheimers Dement. 2016;12(2):144–53.

    Article  PubMed  Google Scholar 

  5. Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37(3):323–9.

    Article  CAS  PubMed  Google Scholar 

  6. Gonzalez DA, Gonzales MM, Resch ZJ, Sullivan AC, Soble JR. Comprehensive evaluation of the functional activities questionnaire (FAQ) and its reliability and validity. Assessment. 2022;29(4):748–63.

    Article  PubMed  Google Scholar 

  7. Marshall GA, Zoller AS, Lorius N, Amariglio RE, Locascio JJ, Johnson KA, et al. Functional Activities Questionnaire items that best discriminate and predict progression from clinically normal to mild cognitive impairment. Curr Alzheimer Res. 2015;12(5):493–502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Neuropathologic correlates of activities of daily living in Alzheimer disease. Alzheimer Dis Assoc Dis. 2006;20(1):56–9.

    Article  Google Scholar 

  9. Marshall GA, Olson LE, Frey MT, Maye J, Becker JA, Rentz DM, et al. Instrumental activities of daily living impairment is associated with increased amyloid burden. Dement Geriatr Cogn Disord. 2011;31(6):443–50.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Halawa OA, Gatchel JR, Amariglio RE, Rentz DM, Sperling RA, Johnson KA, et al. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer’s disease. Alzheimers Res Ther. 2019;11(1):14.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Gonzalez C, Tommasi NS, Briggs D, Properzi MJ, Amariglio RE, Marshall GA, et al. Financial capacity and regional cerebral tau in cognitively normal older adults, mild cognitive impairment, and Alzheimer’s disease dementia. J Alzheimers Dis. 2021;79(3):1133–42.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Marshall GA, Lorius N, Locascio JJ, Hyman BT, Rentz DM, Johnson KA, et al. Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer’s disease spectrum. J Alzheimers Dis. 2014;41(3):719–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Roy K, Pepin LC, Philiossaint M, Lorius N, Becker JA, Locascio JJ, et al. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer’s disease spectrum. J Alzheimers Dis. 2014;42(1):291–300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Marshall GA, Gatchel JR, Donovan NJ, Muniz MC, Schultz AP, Becker JA, et al. Regional tau correlates of instrumental activities of daily living and apathy in mild cognitive impairment and Alzheimer’s disease dementia. J Alzheimers Dis. 2019;67(2):757–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yesavage JA, Sheikh JI. Geriatric Depression Scale (GDS) - recent evidence and development of a shorter version. Clin Gerontol. 1986;5(1–2):165–73.

    Article  Google Scholar 

  16. Rey A. L’examen clinique en psychologie. Paris: Presses Universitaires de France; 1964.

    Google Scholar 

  17. Ryan JJ, Paolo AM. A screening procedure for estimating premorbid intelligence in the elderly. Clin Neuropsychol. 1992;6(1):53–62.

    Article  Google Scholar 

  18. Tombaugh TN. Trail making test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004;19:203–14.

    Article  PubMed  Google Scholar 

  19. R Core Team. R: A language and environment for statistical computing. 4.1.3 ed2022.

  20. Tomaszewski Farias S, Cahn-Weiner DA, Harvey DJ, Reed BR, Mungas D, Kramer JH, et al. Longitudinal changes in memory and executive functioning are associated with longitudinal change in instrumental activities of daily living in older adults. Clin Neuropsychol. 2009;23(3):446–61.

    Article  PubMed  Google Scholar 

  21. Cloutier S, Chertkow H, Kergoat MJ, Gelinas I, Gauthier S, Belleville S. Trajectories of decline on instrumental activities of daily living prior to dementia in persons with mild cognitive impairment. Int J Geriatr Psychiatry. 2021;36(2):314–23.

    Article  PubMed  Google Scholar 

  22. Villeneuve SC, Houot M, Cacciamani F, Verrijp M, Dubois B, Sikkes S, et al. Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer’s disease. Alzheimers Dement (N Y). 2019;5:553–62.

    Article  PubMed  Google Scholar 

  23. Jutten RJ, Harrison JE, Brunner AJ, Vreeswijk R, van Deelen RAJ, de Jong FJ, et al. The cognitive-functional composite is sensitive to clinical progression in early dementia: longitudinal findings from the catch-cog study cohort. Alzheimers Dement (N Y). 2020;6(1):e12020.

    PubMed  Google Scholar 

  24. Dubbelman MA, Sanchez J, Schultz AP, Rentz DM, Amariglio RE, Sikkes SAM, et al. Everyday functioning and entorhinal and inferior temporal tau burden in cognitively normal older adults. J Prev Alzheimers Dis. 2022;9(4):801–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. van der Kant R, Goldstein LSB, Ossenkoppele R. Amyloid-beta-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci. 2020;21(1):21–35.

    Article  PubMed  Google Scholar 

  26. Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76(8):915–24.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–86.

    Article  CAS  PubMed  Google Scholar 

  28. Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139(Pt 5):1551–67.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78(8):961–71.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Gonzalez DA, Clark MJ, Gonzales MM, Benge J. Brief report: an evaluation of item bias on the functional activities questionnaire. Arch Clin Neuropsychol. 2023;38(2):276–82.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge dedication of the participants, their study partners and site personnel who made this study possible.

Funding

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12–2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Author information

Authors and Affiliations

  1. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Mark A. Dubbelman, Kayden J. Mimmack, Rebecca E. Amariglio, Patrizia Vannini & Gad A. Marshall

  2. Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, 60 Fenwood Road, Boston, MA, 02115, USA

    Mark A. Dubbelman, Emily H. Sprague, Rebecca E. Amariglio, Patrizia Vannini & Gad A. Marshall

Authors
  1. Mark A. Dubbelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kayden J. Mimmack
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emily H. Sprague
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rebecca E. Amariglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Patrizia Vannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gad A. Marshall
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the Alzheimer’s Disease Neuroimaging Initiative

Contributions

MAD interpreted the results, wrote the initial draft of the manuscript and integrated comments for the final version. KJM analyzed and interpreted data, prepared the figures, and made multiple revisions of the manuscript. He had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. EHS made multiple revisions of the manuscript. REA gave methodological advice and revised the manuscript. PV gave methodological advice and revised the manuscript. GAM designed and conceptualized the study, supervised the project, gave multiple revisions and integrated comments for the manuscript.

Corresponding author

Correspondence to Mark A. Dubbelman.

Ethics declarations

Ethics approval and consent to participate

Data for ADNI is collected at multiple sites throughout the United States. The local institutional review board for each participating site reviewed and approved the study protocol. All participants provided written informed consent before participating in any study procedures.

Consent for publication

Not applicable.

Competing interests

MAD, KJM, EHS, REA, and PV report no disclosures relevant to the manuscript. GAM has received research salary support for serving as site principal investigator for clinical trials funded by Eisai Inc., Eli Lilly and Company, and Genentech. These relationships are not related to the content in the manuscript.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dubbelman, M.A., Mimmack, K.J., Sprague, E.H. et al. Regional cerebral tau predicts decline in everyday functioning across the Alzheimer’s disease spectrum. Alz Res Therapy 15, 120 (2023). https://doi.org/10.1186/s13195-023-01267-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13195-023-01267-w

Keywords

Alzheimer's Research & Therapy

ISSN: 1758-9193